세계의 당뇨병성 신장 질환 시장 규모 조사 및 예측 : 약제 클래스별, 유통 채널별, 지역별 분석(2023-2030년)

Global Diabetic Nephropathy Market is valued at approximately USD 2.59 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2023-2030. Diabetic Nephropathy is a kidney ailment resulting from prolonged exposure to elevated blood sugar levels, a common consequence of diabetes. It is characterized by the occurrence of proteinuria, where proteins, notably albumin, are detected in the urine. Diabetic individuals face an increased risk of developing this condition. The assessment of glomerular filtration rate serves as a crucial measure to gauge the extent of kidney impairment associated with diabetic nephropathy. The Diabetic Nephropathy market Market is expanding because of factors such as the rise in the prevalence of diabetes and the growing population with cardiovascular diseases. As a result, the demand of for Diabetic Nephropathy has progressively increased in the international market during the forecast period 2023-2030.

Diabetes is often a chronic condition that requires long-term management. The longer individuals live with diabetes, the higher the likelihood of developing complications, including diabetic nephropathy. This chronic nature contributes to a sustained demand for diagnosis, treatment, and management of kidney complications. According to the International Diabetes Federation, in 2021, 537 million adults were diagnosed with diabetes and projected to reach up to 643 million in number by 2030 and 783 million adults by the year 2045. Another important factor that drives the Diabetic Nephropathy market Market is the growing population with cardiovascular diseases. Obesity, hypertension, and dyslipidemia are important risk factors for both diabetes and cardiovascular disease. Since the number of people with cardiovascular diseases grows, the possibility of that more people to will be susceptible to these common risk factors, which can contribute to the development of diabetic nephropathy. According to the World Health Organization (WHO), it was estimated that cardiovascular diseases are recorded as the leading cause of death around the world, which takes an estimated 17.9 million lives annually. Additionally, heart attacks and strokes account for 85% of these cardiovascular disease deaths. Moreover, technological advancements associated with diabetic nephropathy and supportive government initiatives towards the treatment of diabetes is are anticipated to create a lucrative growth opportunity opportunities for the market over the forecast period. However, the high cost associated with diabetic nephropathy and lack of standardization in nephropathy is going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Diabetic Nephropathy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising government and pharmaceutical organization efforts to raise awareness of kidney disease in the region. Awareness programs can provide valuable information about the link between diabetes and kidney disease, encouraging individuals to seek information about their health conditions. Accessible information empowers people to make informed decisions about their health and take proactive steps to prevent complications. The region's dominant performance is anticipated to propel the overall demand of for Diabetic Nephropathy. Furthermore, Asia Pacific is expected to grow fastest during over the forecast period, owing to factors such as increased healthcare spending in the region. Increased healthcare spending can improve access to necessary medical treatments, medications, and healthcare services for individuals with Diabetic Nephropathy. This includes access to dialysis or kidney transplantation for those in advanced stages of the disease.

Major market player included in this report are:

• Janssen Pharmaceuticals, Inc
• AstraZeneca plc
• Aurobindo Pharma Limited
• Teva Pharmaceutical Industries Ltd
• Sanofi S.A.
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Bayer AG
• Par Pharmaceuticals Inc
• F. Hoffmann-La Roche Ltd

Recent Developments in the Market:

• In January 2024, Neuralace Medical, Inc., a pain management technology inventor has announced its innovative product, Axon Therapy (mPNS), which has been cleared by the FDA for the treatment of persistent Painful Diabetic Neuropathy (PDN). This approval is the first time the FDA has cleared a non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for Painful Diabetic Neuropathy.

Global Diabetic Nephropathy Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Drug Class, Distribution Channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class

• Angiotensin Converting Enzyme (ACE) Inhibitors
• Angiotensin Receptor Blockers
• Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
• Mineralocorticoid Receptor Antagonists
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1.Diabetic Nephropathy Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2.Diabetic Nephropathy Market, by Drug Class, 2020-2030 (USD Billion)
  • 1.2.3.Diabetic Nephropathy Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Diabetic Nephropathy Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Diabetic Nephropathy Market Dynamics

• 3.1.Diabetic Nephropathy Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Rise in prevalence of diabetes
    • 3.1.1.2.Growing population with cardiovascular diseases.
  • 3.1.2.Market Challenges
    • 3.1.2.1.High cost associated with diabetic nephropathy.
    • 3.1.2.2.Lack of standardization in nephropathy.
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Technological advancements associated with diabetic nephropathy.
    • 3.1.3.2.Supportive government initiatives towards treatment of diabetes

Chapter 4.Global Diabetic Nephropathy Market Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economical
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Diabetic Nephropathy Market, by Drug Class

• 5.1.Market Snapshot
• 5.2.Global Diabetic Nephropathy Market by Drug Class, Performance - Potential Analysis
• 5.3.Global Diabetic Nephropathy Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
• 5.4.Diabetic Nephropathy Market, Sub Segment Analysis
  • 5.4.1.Angiotensin Converting Enzyme (ACE) Inhibitors
  • 5.4.2.Angiotensin Receptor Blockers
  • 5.4.3.Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  • 5.4.4.Mineralocorticoid Receptor Antagonists
  • 5.4.5.Others

Chapter 6.Global Diabetic Nephropathy Market, by Distribution Channel

• 6.1.Market Snapshot
• 6.2.Global Diabetic Nephropathy Market by Distribution Channel, Performance - Potential Analysis
• 6.3.Global Diabetic Nephropathy Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 6.4.Diabetic Nephropathy Market, Sub Segment Analysis
  • 6.4.1.Hospital Pharmacies
  • 6.4.2.Drug Stores & Retail Pharmacies
  • 6.4.3.Online Pharmacies

Chapter 7.Global Diabetic Nephropathy Market, Regional Analysis

• 7.1.Top Leading Countries
• 7.2.Top Emerging Countries
• 7.3.Diabetic Nephropathy Market, Regional Market Snapshot
• 7.4.North America Diabetic Nephropathy Market
  • 7.4.1.U.S. Diabetic Nephropathy Market
    • 7.4.1.1.Drug Class breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2.Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 7.4.2.Canada Diabetic Nephropathy Market
• 7.5.Europe Diabetic Nephropathy Market Snapshot
  • 7.5.1.U.K. Diabetic Nephropathy Market
  • 7.5.2.Germany Diabetic Nephropathy Market
  • 7.5.3.France Diabetic Nephropathy Market
  • 7.5.4.Spain Diabetic Nephropathy Market
  • 7.5.5.Italy Diabetic Nephropathy Market
  • 7.5.6.Rest of Europe Diabetic Nephropathy Market
• 7.6.Asia-Pacific Diabetic Nephropathy Market Snapshot
  • 7.6.1.China Diabetic Nephropathy Market
  • 7.6.2.India Diabetic Nephropathy Market
  • 7.6.3.Japan Diabetic Nephropathy Market
  • 7.6.4.Australia Diabetic Nephropathy Market
  • 7.6.5.South Korea Diabetic Nephropathy Market
  • 7.6.6.Rest of Asia Pacific Diabetic Nephropathy Market
• 7.7.Latin America Diabetic Nephropathy Market Snapshot
  • 7.7.1.Brazil Diabetic Nephropathy Market
  • 7.7.2.Mexico Diabetic Nephropathy Market
• 7.8.Middle East & Africa Diabetic Nephropathy Market
  • 7.8.1.Saudi Arabia Diabetic Nephropathy Market
  • 7.8.2.South Africa Diabetic Nephropathy Market
  • 7.8.3.Rest of Middle East & Africa Diabetic Nephropathy Market

Chapter 8.Competitive Intelligence

• 8.1.Key Company SWOT Analysis
• 8.2.Top Market Strategies
• 8.3.Company Profiles
  • 8.3.1.Janssen Pharmaceuticals, Inc
    • 8.3.1.1.Key Information
    • 8.3.1.2.Overview
    • 8.3.1.3.Financial (Subject to Data Availability)
    • 8.3.1.4.Product Summary
    • 8.3.1.5.Recent Developments
  • 8.3.2.AstraZeneca plc
  • 8.3.3.Aurobindo Pharma Limited
  • 8.3.4.Teva Pharmaceutical Industries Ltd
  • 8.3.5.Sanofi S.A.
  • 8.3.6.Novartis AG
  • 8.3.7.Sun Pharmaceutical Industries Ltd
  • 8.3.8.Bayer AG
  • 8.3.9.Par Pharmaceuticals Inc
  • 8.3.10.F. Hoffmann-La Roche Ltd

Chapter 9.Research Process

• 9.1.Research Process
  • 9.1.1.Data Mining
  • 9.1.2.Analysis
  • 9.1.3.Market Estimation
  • 9.1.4.Validation
  • 9.1.5.Publishing
• 9.2.Research Attributes
• 9.3.Research Assumption